Triplet Therapeutics is a technology company.
Triplet Therapeutics has raised $49.0M across 1 funding round.
Triplet Therapeutics has raised $49.0M in total across 1 funding round.
Triplet Therapeutics was a biotechnology company founded in 2018 or 2019 that developed antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) to treat repeat expansion disorders (REDs), a group of over 40 genetic diseases including Huntington’s disease, myotonic dystrophy, and spinocerebellar ataxias.[1][3][4] It targeted the DNA damage response (DDR) pathway, the common underlying driver of these disorders, serving patients with unmet needs in neurodegenerative and neuromuscular conditions by aiming to halt disease onset and progression upstream of existing approaches.[1][2][3] The company raised $59 million (some reports note over $80 million including debt) from investors like Atlas Venture and MPM Capital but ceased operations in October 2022 due to financial struggles and clinical toxicity issues with its lead compound, leading to an asset sale via assignment for the benefit of creditors (ABC).[1][2][5]
Triplet Therapeutics emerged from insights into human genetics linking the DDR pathway to REDs, founded by Nessan Bermingham, Ph.D. (CEO, serial biotech entrepreneur and Atlas Venture venture partner), Atlas Venture, and Andrew Fraley, Ph.D..[3] Bermingham, with prior experience in biotech ventures, assembled the team to pioneer a new treatment paradigm, launching with a $59 million financing round announced by Pfizer in late 2020 amid a biotech funding boom fueled by Covid-19.[1][3] Early traction included filing 7 patents on topics like DNA, gene expression, and abnormal psychology, and initiating the Shield-HD study for Huntington’s, which continued under CHDI after shutdown.[1][2] However, promising preclinical results gave way to central nervous system toxicity in trials, short runway, and investor fatigue, culminating in quiet closure announced by Bermingham on LinkedIn.[2][5]
Triplet rode the genetic medicines wave in biotech, targeting REDs amid surging interest in RNA therapeutics (ASOs/siRNAs) post-Alnylam successes and the 2020 funding surge.[1][3] Timing aligned with DDR pathway validation in neurodegeneration, but market forces like clinical toxicity risks, investor pullback post-Covid boom, and short runways exposed startup vulnerabilities in capital-intensive biotech.[2][5] Its assets' acquisition via ABC preserved value for creditors (including venture lenders), influencing the ecosystem by enabling tech transfer—e.g., Shield-HD data to CHDI—while underscoring tools like ABCs as faster alternatives to bankruptcy for distressed biotechs.[5] This reflects broader pressures on early-stage platforms without near-term clinical wins.
Triplet's story exemplifies biotech's high-stakes gamble: bold DDR targeting promised paradigm shifts for REDs, but toxicity and funding droughts led to asset liquidation rather than breakthroughs.[2][5] Its IP and data live on through undisclosed buyers, potentially fueling rivals in genetic therapies amid advancing CRISPR and RNA platforms. Looking ahead, trends like AI-driven target validation and derisked pipelines will shape survivors, but Triplet warns of execution pitfalls in a maturing, cash-conscious biotech landscape—reminding investors that even well-funded platforms need clinical momentum to endure.[1][2]
Triplet Therapeutics has raised $49.0M in total across 1 funding round.
Triplet Therapeutics's investors include Atlas Venture, OrbiMed.
Triplet Therapeutics has raised $49.0M across 1 funding round. Most recently, it raised $49.0M Series A in December 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2019 | $49.0M Series A | Atlas Venture, OrbiMed |